Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanda Castro

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Neurology|April 2, 2011
Functional treatments in multiple sclerosisArdith M Courtney, Wanda Castro-Borrero, Scott L Davis, et al.
Nature Clinical Practice. Urology|February 10, 2009
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and managementSophie G Fletcher, Wanda Castro-Borrero, Gina Remington, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 24, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational ProgramMarco Salvetti, Sibyl Wray, Gereon Nelles, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 10, 2017
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE studyRalph Hb Benedict, Stanley Cohan, Sharon G Lynch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2017
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab betaGavin Giovannoni, Heinz Wiendl, Benjamin Turner, et al.
Therapeutic Advances in Neurological Disorders|March 19, 2021
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early terminationLudwig Kappos, Stanley Cohan, Douglas L Arnold, et al.
Therapeutic Advances in Neurological Disorders|July 12, 2012
Current and emerging therapies in multiple sclerosis: a systematic reviewWanda Castro-Borrero, Donna Graves, Teresa C Frohman, et al.
Clinical & Translational Immunology|December 16, 2014
Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosisVahid Farrokhi, Reza Nemati, Frank C Nichols, et al.
Experimental Neurology|November 21, 2016
iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury responseAlexandra M Nicaise, Erin Banda, Rosa M Guzzo, et al.
Advances in Therapy|June 3, 2016
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple SclerosisJames G Krueger, Leon Kircik, Firas Hougeir, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Neurology|April 2, 2011
Functional treatments in multiple sclerosisArdith M Courtney, Wanda Castro-Borrero, Scott L Davis, et al.
Nature Clinical Practice. Urology|February 10, 2009
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and managementSophie G Fletcher, Wanda Castro-Borrero, Gina Remington, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 24, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational ProgramMarco Salvetti, Sibyl Wray, Gereon Nelles, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 10, 2017
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE studyRalph Hb Benedict, Stanley Cohan, Sharon G Lynch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2017
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab betaGavin Giovannoni, Heinz Wiendl, Benjamin Turner, et al.
Therapeutic Advances in Neurological Disorders|March 19, 2021
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early terminationLudwig Kappos, Stanley Cohan, Douglas L Arnold, et al.
Therapeutic Advances in Neurological Disorders|July 12, 2012
Current and emerging therapies in multiple sclerosis: a systematic reviewWanda Castro-Borrero, Donna Graves, Teresa C Frohman, et al.
Clinical & Translational Immunology|December 16, 2014
Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosisVahid Farrokhi, Reza Nemati, Frank C Nichols, et al.
Experimental Neurology|November 21, 2016
iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury responseAlexandra M Nicaise, Erin Banda, Rosa M Guzzo, et al.
Advances in Therapy|June 3, 2016
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple SclerosisJames G Krueger, Leon Kircik, Firas Hougeir, et al.
Pageof 2